Esperion Therapeutics
ESPR
#6317
Rank
A$1.20 B
Marketcap
A$5.05
Share price
3.61%
Change (1 day)
71.58%
Change (1 year)

P/S ratio for Esperion Therapeutics (ESPR)

P/S ratio as of February 2026 (TTM): 2.67

According to Esperion Therapeutics's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -1.80. At the end of 2025 the company had a P/S ratio of 1.76.

P/S ratio history for Esperion Therapeutics from 2013 to 2025

PS ratio at the end of each year

Year P/S ratio Change
20251.7630.1%
20241.35-53.75%
20232.92-51.95%
20226.0856.69%
20213.8831.08%
20202.96-73.21%
201911.1
2018N/A
2017N/A
2016N/A
2015N/A
2014N/A
2013N/A

P/S ratio for similar companies or competitors

Company P/S ratio P/S ratio differencediff. Country
Pfizer
PFE
2.39-10.24%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
5.52 106.76%๐Ÿ‡บ๐Ÿ‡ธ USA
Ultragenyx Pharmaceutical
RARE
3.68 38.05%๐Ÿ‡บ๐Ÿ‡ธ USA
Lexicon Pharmaceuticals
LXRX
5.95 123.04%๐Ÿ‡บ๐Ÿ‡ธ USA
Amicus Therapeutics
FOLD
7.49 180.68%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
3.51 31.61%๐Ÿ‡บ๐Ÿ‡ธ USA